Nanovis Announces Commercial Launch of New Nanosurface Technology on Spinal Interbody Implants

Nanovis announced the commercial launch of its bioceramic nanotube enhanced FortiCore interbodies following a successful alpha launch.

The FortiCore interbodies are designed with a unique, proprietary, patent protected bio-ceramic enhanced titanium nanotube surface. The nanotubes are applied to a deeply porous, fully interconnected titanium scaffold intermolded with a PEEK core for preferred modulus and plain X-ray visualization.
 
A few innovators from select areas around the United States were the first in the world to use this new nanotechnology.
 
“Implant surface technologies have advanced tremendously. Surgeons can now use interbodies with the most advanced nanotechnology, deep interconnected pores, and excellent visualization. I’m excited by the state of the art in the field today compared to where we were even a year ago. Applying these technologies to an entire spine portfolio offers us the potential to offer patients better fixation after fusion surgeries,” said Douglas Pahl, M.D., and Todd Bonvallet, M.D., of The Hughston Clinic, Columbus, Ga.
 
“The FortiCore scaffold has performed well for my patients in lumbar and cervical fusions, providing a large area of highly porous, nanotube enhanced surface for bone to interface with before bone has time to grow through the implant. I appreciate that the PEEK core allows me to assess traditional fusion without forcing the use of expensive scans that expose the patient to more radiation,” added John Gorup, M.D., of Indiana Spine Center, West Lafayette, Ind.

The FortiCore interbodies are designed with a unique, proprietary, patent protected bio-ceramic enhanced titanium nanotube surface. The nanotubes are applied to a deeply porous, fully interconnected titanium scaffold intermolded with a PEEK core for preferred modulus and plain X-ray visualization.
 
“I’m interested in how nanotechnology can help my patients. The combination of cutting-edge nanotechnology on a deeply porous titanium scaffold with excellent visualization of the graft chamber has turned out to be a considerable improvement over traditional PEEK interbodies for my patients. I’m interested in what Nanovis will do with nanosurfaced pedicle screws and the bactericidal bone growth surface they’ve been working on,” said Jerome Kolavo, M.D., of Northwestern Medicine Orthopaedics, Chicago.
 
“I’ve watched this nanotechnology portfolio from shortly after it’s invention. I’m happy with how the interbodies with this nanotechnology performed for my patients so far. Now that we have surfaces designed for bone growth, we need to advance the research to kill any bacteria that tries to colonize the implants during surgery and subsequent wound healing, before that bacteria can cause implant loosening or symptomatic infections,” said Alan McGee, M.D., of Orthopedics North East, Fort Wayne, Ind.

Nanovis’ fixation technology platforms continue to perform well commercially and in testing. The FortiCore interbody system with a deeply porous titanium scaffold, intermolded with a PEEK core is attractive to surgeons who want deep porosity and the visualization and modulus benefits of PEEK. Nanovis will soon reveal favorable testing results from comparison tests of their nanotube-bioceramic surface compared to non-nanorough titanium, acid-etched nanorough titanium and calcium phosphate coated titanium.
 
“Nanovis is pleased with the success of this alpha launch. The feedback from these innovative and discerning surgeons was positive, encouraging, and primes us for the full commercial launch of our nanotube enhanced FortiCore interbodies. We are committed to reducing the pain and suffering from implant loosening, and plan to apply our nanotube surface on our entire portfolio of spinal implants as fixation challenges occur in every spinal implant application,” stated Nanovis CEO Matt Hedrick.
 
Nanovis is a platform technology-driven growth company committed to helping surgeons and hospitals achieve excellent fixation and infection outcomes using advanced nanotechnology platforms. Its fixation technologies offer surgeons and hospitals aspects of fixation, visualization, and durability. Nanovis’ developmental infection technology platforms promise to offer surgeons and hospitals bactericidal solutions. Nanovis is actively preparing new surgeons and distributors for expansion of the nanotube enhanced FortiCore interbodies.

Nanovis’ mission is to develop science-enhanced, life-improving technologies. The company’s patented and proprietary regenerative technology platforms provide differentiated surface advantages enabling the potential for existing medical devices to achieve new outcomes. Focused on aggressive, sustainable growth across multiple markets, Nanovis is commercializing science-driven platforms: the deeply porous scaffold currently available with the FortiCore line of interbody fusion devices (deeply porous ti scaffold licensed from Sites Medical); an advanced nano-surface technology in development; a surface technology with anti-colonization and anti-microbial capabilities in pre-clinical studies, and a localized infection technology targeted toward anti-microbial resistant bacteria in pre-clinical studies.